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Abstract Inhaled steroids are recommended for long-term control of asthma, but their use may be limited in young 
children because of difficulties in using the associated inhaler device.The use of nebulizers may help to overcome this issue, 
without compromising therapeutic efficacy or safety.This I4-week, multicentre, randomized, controlled, open-label, parallel- 
group study compared the efficacy and safety of nebulized corticosteroids in paediatric patients (aged 6 months to 6 years) 
with severe persistent asthma. Beclometasone dipropionate (BDP) 800 pg day’ suspension for nebulization and 
budesonide (BUD) 750 pgdayl given by nebulization in a twice-daily regimen, and when used in addition to the usual 
maintenance therapy, resulted in comparable clinical efficacy across all parameters.The primary efficacy endpoint was the 
number of patients who did not experience any major exacerbation, this being 40.4% and 5 I .7% in the BDP and BUD 
groups respectively in the ITT population (P=O.28), and the mean number of global exacerbations (major plus minor) 
decreased respectively by -37.5% in the BDP group and -23.3% in the BUD group. Both treatments were also associated 
with marked reductions in the number of nights with wheezing and the number of days of oral steroid use. Moreovev; the 
two treatment groups had a similar adverse-event incidence and profile. Only I I adverse events were reported, and no 
serious adverse events were related to treatment. Urinary cotiisol and the time course of height and weight were 
unaffected by both treatments, and BDP was confirmed to have a neutral effect on bone metabolism. In conclusion, this 
study demonstrates that both BDP 800 pgdayl suspension for nebulization and BUD 750 pgda)rl administered by 
nebulization are effective, with an acceptable safety profile, for treatment of severe persistent asthma in infants and young 
children. 
0 2003 Elsevier Science Ltd 
INTRODUCTION 
Despite the growing knowledge of the pathogenesis of 
asthma, the prevalence of this disease appears to be on 
the increase. Indeed, asthma is now the most common 
chronic disease amongst children, affecting some 5-l 0% 
of children under the age of 6 years: around 10% of 
asthmatic children develop symptoms before the age of 
I year, and over 50% by the age of 2 years. 
The prevention of long-term respiratory complications 
associated with asthma is based on early and adapted 
management of the condition, in particular by using anti- 
inflammatory therapy as early as possible. Furthermore, 
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administration via inhalation is the preferred route for 
asthmatic children on account of its rapid action, and also 
its favourable safety:efficacy ratio compared with oral 
therapy. 
In infants and young children suffering from asthma, 
selection of the method of delivery of medication is 
essentially dictated by the option that requires minimum 
co-operation, and during acute asthma attacks 
nebulization offers this advantage, especially in young 
dyspnoeic children. Although the introduction of 
metered-dose inhalers (MDls) and dry powder inhalers 
(DPls) have reduced the use of nebulized therapy, 
problems with hand-to-lung co-ordination and 
inspiratory flow are common in children. Nebulizers can 
overcome both the co-ordination problems associated 
with MDI use and the inspiratory difficulties 
encountered with DPls (I ,2). 
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Beclometasone dipropionate (BDP) is a steroid that 
has been in clinical use as an inhalation anti-inflam- 
matory treatment for asthma since the 1970s and 
remains the reference drug for inhaled anti-inflam- 
matory therapy in asthma.The purpose of this study was 
to evaluate the efficacy and safety of BDP suspension for 
nebulization in treating severe asthma in infants and 
young children when compared with the currently 
available nebulized formulation of the steroid 
budesonide (BUD). 
MATERIALS AND METHODS 
Patients 
A total of 130 outpatient infants or children, male and 
female, aged 6 months to 6 years, with severe persistent 
asthma were selected for participation in the study. 
Severe persistent asthma was defined as asthma (a 
history of at least three episodes of wheezing dyspnoea) 
associated with at least one of the following severity 
criteria: daily wheezing, with or without cough, for at least 
a fortnight before inclusion; experiencing at least one 
exacerbation per month requiring oral steroid therapy 
during the 3 months preceding inclusion in the study. 
Patients with an allergy to any of the constituents of the 
test products or concomitant therapies, presenting with 
other pulmonary (including cystic fibrosis, cardio- 
pulmonary malformation, immune deficiency, and active 
tuberculosis) or major non-pulmonary concomitant 
(including non-treated gastro-oesophageal reflux, and 
cardiac and/or renal and/or hepatic and/or neurological 
disease) conditions, or taking long-acting &-agonists were 
excluded from participation in the study. 
The study was approved by the Ethics Committee of 
Hopital Purpan,Toulouse, and was conducted according 
to Good Clinical Practices Guidelines. 
Study design 
A I4-week, multicentre, randomized, controlled, parallel- 
group, open-label study. Patients who met inclusion and 
exclusion criteria were randomized to one of two 
treatment arms: BDP 800 pgday-I b.i.d. suspension for 
nebulization (Clenil A@, Chiesi Farmaceutici SpA, Parma, 
Italy), or BUD 750 pgday’ b.i.d. (Pulmicort@ Repsules, 
Astra Pharmaceuticals Ltd., Kings Langley, Herts, U.K.). 
Both drugs were administered using a Pari Boy Junior 
nebulizer (Pari GmbH, Starnberg, Germany). 
Following a 2-week run-in phase with maintenance 
therapy of oral ketotifen l-2 mg day’ (Zaditen@, 
Novartis Pharmaceuticals, Basel, Switzerland), patients 
were randomized to I2 weeks’ treatment with either 
BDP or BUD, plus ketotifen. 
Patients were assessed at various stages during the 
study: during the initial 2-week run-in period (visit I), at 
2 weeks (visit 2), and thereafter at 4-weekly intervals 
(visits 3-5). 
Concomitant treatments permitted in the study when 
necessary were certain bronchodilators, oral steroids, 
and antibiotics. The bronchodilators authorized during 
the study were nebulized salbutamol, terbutaline, or 
ipratropium bromide, or inhaled salbutamol or 
terbutaline. Antihistamines other than ketotifen, inhaled 
steroids other than those authorized in the study, inhaled 
cromones, &-agonists other than salbutamol and 
terbutaline in maintenance therapy, and maintenance 
treatment with anticholinergics or theophyllines were 
excluded. Informed and written consent was obtained 
from the parents of the patients prior to study inclusion. 
Assessments 
The primary efficacy evaluation criterion in the study 
was the percentage of patients who did not experience 
at least one major exacerbation during the study 
treatment period (after visit 2). A major exacerbation 
was defined as failure in I hour of two nebulizations of 
salbutamol, terbutaline, or ipratropium bromide, or 
two/three inhalations of two puffs of salbutamol or 
terbutaline, and the need for oral steroid therapy for at 
least 2 consecutive days. Major secondary efficacy 
endpoints were the number of major plus minor 
exacerbations, the time to onset of the first major 
exacerbation, the number of nebulizations or inhalations 
of salbutamol, the mean duration of oral steroid therapy, 
the number of days and nights with wheezing and with 
cough, and parental absenteeism from work due to child 
disease.The primary safety evaluation parameter in the 
study was the concentration of urinary deoxypyridino- 
line measured by ELISA and expressed by the urinary 
deoxypyridinoline: urinary creatinine ratio, to determine 
the effect of the steroid treatments on bone resorption. 
Secondary safety criteria included the cortisol: creatinine 
ratio in the first morning urine sample, height and weight 
gains between visits 2 and 5, and adverse events reported 
by the parents. Clinical safety was assessed at each visit 
during the study. 
Statistical analysis 
Efficacy was analysed on the basis of intent-to-treat (ITT) 
and per protocol (PP) populations, and safety was 
analysed in all patients who received at least one 
randomized treatment unit. The primary analysis was 
undertaken on the ITT population. 
Group comparisons for the primary efficacy endpoint 
involved comparison by the Chi-square test, and for 
secondary endpoints by the t test or Wilcoxon’s test. 
Group comparisons for primary and secondary safety 
criteria used two-way analysis of variance for repeated 
measurements. Description by body system for adverse 
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events and intergroup comparisons used the Chi-square 
test. 
RESULTS 
Patient population 
Of the I30 patients (mean age 2. I + I .4 years) screened 
for the study in 24 centres, 120 were randomized to 
treatment: 58 to BDP, and 62 to BUD.The number of 
major exacerbations after visit 2 was not available for 
three patients (one in the BDP group and two in the 
BUD group), who were then eliminated from the ITT 
population, and I8 patients (five in the BDP group and I3 
in the BUD group) presented at least one major 
protocol violation. In total, therefore, I I7 patients were 
analysed in the ITT population (57 treated with BDP and 
60 with BUD) and 99 in the PP population (52 treated 
with BDP and 47 with BUD). The groups were 
homogeneous in terms of demographic characteristics at 
selection (Table I). 
Evaluation of efficacy 
All results obtained from the ITT population were 
confirmed by those of the PP population, and 
consequently only ITT results are presented here. 
Similar results were demonstrated for the two 
treatment arms for all efficacy parameters (Table 2, 
Figures l-5) during the entire randomized treatment 
period, with no statistically significant differences noted 
between the groups. 
Examination of the primary efficacy endpoint 
demonstrated that 40.4% of BDP-treated patients and 
5 1.7% of BUD patients did not experience any 
exacerbations during the treatment period, with the 
difference between the groups being non-significant 
(PzO.22). The mean number of global exacerbations 
(major plus minor) decreased respectively by -37.5% in 
the BDP group and -23.3% in the BUD group. No 
significant differences were found between the groups 
(PzO.28). The mean time to onset of the first major 
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FIGURE I. Time to onset of the first major exacerbation. ITT 
population. 
exacerbation was 46.3 days for BDP patients vs 46. I 
days for BUD patients, with no difference evident 
between the two groups (PzO.72) (Figure I). 
The two treatment groups were subsequently found 
to have produced a significant and similar reduction in 
the number of exacerbations (major + minor) per 
patient per day between the run-in and treatment 
periods: down by 37.5% for the BDP group and by 23.3% 
for the BUD group (P=O*60) (Table 3). 
Both BDP and BUD produced particularly marked 
effects with respect to the mean number of days of oral 
steroid therapy, with significant reductions of 66.7% for 
the BDP group (P~O.002) and 58.3% for the BUD group 
(P=O*OO7) (Figure 2). No significant differences were 
found between the groups for the randomized treatment 
period (P=O. 19). 
The mean number of nebulizations or inhalations of 
salbutamol varied significantly during the study, with 
significant reductions of 61.8% for the BDP group 
(P<O*OOO I) and 57.8% for the BUD group (P<O*OOOl), 
and were similar for the two groups during the 
treatment period (PzO.22) (Figure 3). 
The mean number of days with wheezing varied 
significantly during the study, with significant reductions 
of 53. I % for the BDP group (P=O*OO I) and 64.3% for the 
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BUD group (P<O.OOOl) (Figure 4). No significant 
differences were found between the groups for the 
randomized treatment period (P=O. 13). 
The mean number of nights with wheezing during the 
study was notably reduced, with significant reductions of 
63% for the BDP group (P=O.OOl) and 72.7% for the 
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BUD group (kO.002) (Figure 5).The difference between 
the two treatments was significant (PzO.02). 
The mean number of days with cough varied 
significantly during the study, with reductions of 49.3% 
for the BDP group (P<O.OOOl) and 49.2% for the BUD 
group (WO.000 I). Between-group differences were non- 
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significant for the entire randomized treatment period the BDP and BUD groups also had similar increases in 
(P=O*23). bodyweight and height during the study. 
The mean number of nights with cough also varied 
considerably during the study, with significant reductions 
of 55.6% for the BDP group (P<O.OOOl) and 45.5% for 
the BUD group (kO.004). No significant difference was 
found between the two treatments (P=O*O7). 
Finally, according to patient and investigator 
assessments of treatment, some 40-5 I% of patients 
considered treatment with either BDP or BUD to be 
‘good’ or ‘very good’ at treatment end in both the ITT 
and PP populations. 
Evaluation of safety 
Assessment of clinical safety of the two treatments was 
based on I30 subjects. There was no change in bone 
metabolism, as indicated by a static urinary deoxy- 
pyridinoline : urinary creatinine ratio, for either group 
(Table 4). Urinary cortisol and urinary cortisolkreatinine 
ratios were not significantly affected during treatment 
for both the BDP and BUD groups (Table 5). Patients in 
In total, 4 I7 emergent adverse effects were reported 
during the study, 79 of which occurred in the run-in 
phase and 338 in the randomized treatment period. Of 
the 338 adverse events observed in the randomized 
treatment period, 168 were reported in the BDP group 
and 170 in the BUD group. However, only I I adverse 
events in total (five in the BDP group and six in the BUD 
group) were considered to be treatment-related. 
Furthermore, none of the I6 serious adverse events 
reported by I4 patients during the study (eight adverse 
events and seven patients in each group) were found to 
be related to treatment. Overall, the frequency and 
profile of adverse events were equivalent for the two 
treatments, with side-effects generally being associated 
with the ear, nose, and throat, and respiratory system. 
DISCUSSION 
Inhaled steroid therapy is recommended for the long- 
term control of asthma in children (3). However, some 
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young children may experience co-ordination and/or 
inspiratory difficulties when using available MDls or DPls 
and in such instances nebulization may be useful since 
this method of administration requires minimum co- 
operation. Indeed, the efficacy of steroid therapy, namely 
BUD, given via nebulization as a basic treatment for 
infants and children with asthma has been confirmed in a 
number of studies undertaken to date (4-8). 
This present study was to designed to compare the 
efficacy and safety of BDP suspension for nebulization 
with those of BUD, both given via a nebulizer as a l2- 
week treatment for severe persistent asthma in infants 
and children. 
The results of the study demonstrated that nebulized 
forms of BDP and BUD had similar effects with regard to 
the various efficacy criteria assessed, which included 
asthma exacerbations (major and minor) and symptoms, 
and the use of rescue medication.The results were not 
biased for separation between major and minor 
exacerbations since no difference was demonstrated 
during a post-hoc analysis of total exacerbations. Both 
treatments had a particularly notable effect in reducing 
the number of nights of wheezing and days of oral 
steroid use. Furthermore, a similar adverse-event profile 
was reported for the two treatments. 
Efficacy was primarily assessed by the incidence of 
major and minor exacerbations during the treatment 
period, analysed separately. These two parameters were 
defined as bronchodilator treatment failure associated 
with a non-planned physician visit for minor exacerba- 
tions, and bronchodilator treatment failure associated 
with a non-planned physician visit plus oral steroid pres- 
cription for major exacerbations. Oral steroid prescrip- 
tions are mainly dependent on physician habit and could 
vary significantly from one physician to another.As major 
and minor exacerbations differ only by the prescription 
of oral steroids, it was logical to pool them in a post-hoc 
analysis to explore an overall parameter termed ‘non- 
planned physician visit’ which is a very important 
parameter for the follow-up of asthmatic children.The 
results of this analysis are shown in Table 3, expressed as 
the number of exacerbations (major + minor) per 
patient per day, and confirm the initial findings - i.e. a 
comparable clinical effect between BDP 800 ug day-’ 
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b.i.d. suspension for nebulization and nebulized BUD 
750 pg day-1 b.i.d. 
There are few previous comparative studies of inhaled 
BDP and BUD in asthmatic children.Two double-blind, 
randomized, crossover trials have shown equivalent 
efficacy of 400 pg day’ BDP and BUD (used with spacer) 
over I month, as measured by twice-daily PEFRs and 
recorded symptoms (9, IO). In another study in I2 
asthmatic children, significant improvements in lung 
function tests were achieved following administration of 
400 pg day-’ BDP and BUD over 2 weeks; there was no 
significant difference in efficacy between the two 
treatments (I I). In a fourth study, BUD (used with 
spacer) and BDP 100 pg twice-daily was administered 
over 3 weeks in a double-blind cross-over trial in 21 
children. Morning and evening PEFR values were 
significantly higher with BUD; however, FEV, values for 
the two regimens were not statistically different (I 2). 
The results of this study are consistent with those of 
a previous study of 127 children with mild to moderate 
persistent asthma aged from 6 to I4 years. The 
administration of BDP 800 pg day-l b.i.d. suspension for 
nebulization and BUD IO00 pg day’ b.i.d. via nebulizer 
produced significant and similar beneficial effects vs 
baseline in final mean PEFR, FEV,, and the use of rescue 
medication, with acceptable safety and tolerability 
profiles (I 3). 
The results of this study support the clinical use of 
BDP 800 pg day’ suspension for nebulization for the 
treatment of infants and young children with severe 
persistent asthma. BDP suspension for nebulization is as 
safe and clinically effective as nebulized BUD and appears 
to be a suitable and valuable therapeutic alternative for 
asthma in this young patient population. 
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